1. Home
  2. EVN vs FULC Comparison

EVN vs FULC Comparison

Compare EVN & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Municipal Income Trust

EVN

Eaton Vance Municipal Income Trust

HOLD

Current Price

$10.31

Market Cap

430.6M

Sector

Finance

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$7.79

Market Cap

462.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVN
FULC
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
430.6M
462.2M
IPO Year
1998
2019

Fundamental Metrics

Financial Performance
Metric
EVN
FULC
Price
$10.31
$7.79
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$16.38
AVG Volume (30 Days)
72.4K
994.3K
Earning Date
01-01-0001
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.59
$2.32
52 Week High
$11.23
$15.74

Technical Indicators

Market Signals
Indicator
EVN
FULC
Relative Strength Index (RSI) 33.52 49.40
Support Level $10.27 $7.40
Resistance Level $11.15 $8.01
Average True Range (ATR) 0.13 0.45
MACD -0.06 0.11
Stochastic Oscillator 26.17 85.62

Price Performance

Historical Comparison
EVN
FULC

About EVN Eaton Vance Municipal Income Trust

Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: